Navigation Links
University of Kentucky offers stroke stem cell trial
Date:1/13/2012

LEXINGTON, Ky. (Jan. 13, 2011) The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult stem cell product, on patients with acute ischemic stroke. The phase II clinical trial, known as Atherys stroke protocol B01-02, was recently approved by UK's institutional review board.

"Adult stem cells may have great potential in stroke treatment, and we need to approach it scientifically. We are excited to be the first to bring a clinical trial of stem cells for stroke to Kentucky," said Dr. Michael Dobbs, director of the UK HealthCare Stroke Affiliate Network and principal investigator on the stem cell trial.

Despite recent advances in interventional ischemic stroke treatment, medical therapy for the treatment of stroke has largely been limited to tPA, the clot-busting drug that received FDA approval in 1996.

Using stem cells in the treatment of stroke represents a novel approach to treating the damage caused by stroke. Studies of animal models suggest that stem cell therapy may offer a unique neuro-protective effect, and further investigation as to the mechanism of this benefit is currently underway.

MultiStem is also being studied as a potential treatment for a variety of diseases, with the therapy already successfully completing a Phase I trial in patients suffering from Graft Versus Host Disease (GVHD), a potentially deadly complication of bone marrow transplantation in cancer patients.

"UK's selection as one of the first sites for this study exemplifies our position as a national leader in cutting edge stroke therapy and research. By pioneering new approaches to stroke treatment, we are doing our part to ensure that our stroke patients receive the absolute best care possible," Dobbs said.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
2. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
3. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Smithsonian Institution, Arizona State University announce education and research partnership
6. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
7. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
8. Arizona State Universitys Decision Theater offers balance to an off-kilter world
9. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
10. Herzing University Online Launches Master and Bachelor of Science Degrees in Nursing
11. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Recently, SoCal CEO Magazine staff was ... their third in a series of six workshops where people with ... helped place the mosaic tiles in their permanent location under the ... and Greg Maxwell. , This mural project began in March ... root over three years ago with the goal of promoting ...
(Date:6/19/2013)... Food and Drug Administration (FDA) announced last week the approval ... MemoryShape™. , The FDA approved Sientra/Silimed in March 2012 and ... of the MemoryShape™ implant on June 14, 2013. It ... years old or older and in breast reconstruction of women ... six years of data from 955 women participating in trials. ...
(Date:6/19/2013)... years, the mantra of neurologists treating stroke victims has been ... emergency room quickly to receive a drug that dissolves the ... much brain tissue is saved or lost. , ... timing of giving the intravenous drug known as a ... of ischemic (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... cancer is many fold higher in persons over 65 ... on how best to treat these older cancer patients. ... clinical trials, those elderly patients who are eventually included ... elderly patient population is not well represented in clinical ... is now starting a new phase 2 trial in ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Fit Body ... Laing recently held a charity boot camp in order to ... The fitness boot camp franchise hosted the Brent ... 11 a.m. with 75 boot camp participants and collected over ... boot camp marks the second fundraiser held for Orlando local ...
Breaking Medicine News(10 mins):Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2
... Milestones in Quarter, SAN JOSE, Calif., Nov. 13 ... or "the Company") today,announced results for the third quarter ... $365,000 in the prior year period,resulted in a net ... a net,income of $49,000 ($.01 per share) for the ...
... its established Life Sciences North American practice building upon the ... ... PHILADELPHIA, Nov. 13 Business & Decision, (http://www.businessdecision.com ) announced the ... focus on providing,Pharmaceutical, Biotechnology, Medical Device and CRO companies with a,range ...
... a single enzyme, telomerase, is associated with the uncontrollable ... percent of all of human cancers. Since the mid-1990s, ... have eyed the enzyme as an ideal target for ... working at The Wistar Institute have brought this goal ...
... Actress and new mom calls vaccine ,family priority, this season ... a Golden Globe (for Alias ) and the heart ... this flu season is to protect the health of the ... influenza, and more than 100 children die every year from ...
... who undergo LDLT develop liver cirrhosis with ... vascular dilatation and collateral pathways. Thus, various ... occur, and adult recipients often present characteristic ... Kyoto University Hospital, Japan (Hori T, Yagi ...
... suggests that the presence or absence of two proteins may ... , One of the proteins, called ErbB-4, is important for ... the body. The second protein, called Wwox, is a tumor ... and it is missing in many breast cancers. Scientists dont ...
Cached Medicine News:Health News:Human Pheromone Sciences Announces Third Quarter Results 2Health News:Human Pheromone Sciences Announces Third Quarter Results 3Health News:Human Pheromone Sciences Announces Third Quarter Results 4Health News:Business & Decision Brings its eClinical Life Sciences Industry offering to North America 2Health News:Business & Decision Brings its eClinical Life Sciences Industry offering to North America 3Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:Jennifer Garner Puts Flu Shot in the Spotlight 2Health News:Jennifer Garner Puts Flu Shot in the Spotlight 3Health News:Jennifer Garner Puts Flu Shot in the Spotlight 4Health News:2 proteins may be survival markers in some breast cancers 2Health News:2 proteins may be survival markers in some breast cancers 3
(Date:6/19/2013)... June 19, 2013 Amerivet Solutions, LLC ... all branches of government from Federal to Municipal, ... their facilities to include complex metal design and ... some very complex aluminum parts for the Defense ... our capabilities to service government contracts," states ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
Breaking Medicine Technology:Amerivet Solutions Expands to Manufacture Complex Metal Designs 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
... 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the ... advanced in-vitro diagnostic ("IVD") company, today announced that it ... fiscal quarter ended June 30, 2011 ("1Q FY2011") before ... The Company,s senior management will host an earnings ...
... 4, 2011 Reportlinker.com announces that ... available in its catalogue: ... Markets, Players and Prospects ... Microneedle technology is an ...
Cached Medicine Technology:China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2011 on August 16, 2011 2Microneedle Drug Delivery: Technology, Devices, Markets, Players and Prospects 2Microneedle Drug Delivery: Technology, Devices, Markets, Players and Prospects 3
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... light source is a superior choice for ... surgery, headlamps, and dental curing. This is ... light weight, compact and cost competitve with ... light source utilizes the latest in Cermax ...
... The AtheNA Multi-Lyte Test System* ... designed to simultaneously perform multiple assays ... one well. It offers a simple ... ELISA testing, providing improved clinical sensitivity ...
... VITROS 350 Chemistry System offers easy operation, maintenance, ... primary, STAT, or back-up to the powerful VITROS ... get the job done right the first time. ... Systems are efficient, dependable, and easy-to-use. The VITROS ...
Medicine Products: